The useful question is what changes for users, developers or buyers, and whether the announcement stays industry context or becomes something people can actually use.

The prostate gland, roughly walnut-sized at birth, gradually enlarges in most men, sometimes pressing on the urethra and obstructing urine flow. Known as benign prostatic hyperplasia (BPH), this condition affects about half of men by age 60 and nearly 90% by age 85. Symptoms such as frequent urination and interrupted sleep can disrupt daily life, prompting many to seek medical intervention.

Initial management often includes lifestyle changes like exercise and reduced evening caffeine or alcohol. Medications may follow but can cause side effects such as dizziness or erectile dysfunction. For those seeking alternatives, minimally invasive procedures like Rezūm Water Vapor Therapy use steam to shrink excess tissue, offering symptom relief within weeks and lasting up to five years.

For moderate to severe cases, laser-based treatments like GreenLight XPS vaporize overgrown tissue with minimal bleeding, enabling quick recovery and same-day discharge. Clinical studies show sustained symptom relief for up to 15 years, with 86% of patients reporting stable or improved sexual satisfaction. Over one million men worldwide have undergone this procedure.

In complex cases, HoLEP removes excess tissue entirely using the Lumenis Pulse 120H Holmium Laser with MOSES 2.0 Technology. This method reduces treatment time and complications, allowing 90% of patients to leave the hospital the same day. With a low reoperation rate, HoLEP provides long-term relief for severe BPH.